“WE ARE LOOKING AT OPPORTUNITIES”
How was 2015 for you? Today we have 3,000 qualified employees and are the biggest player in the Turkish pharmaceuticals industry. We have been the sector leader since 2001. In 2015 we produced 195 million packets of medicines. Including our TL 1 billion in domestic sales, our sub-contracted production and our exports, at the end of 2015 our consolidated turnover stood at approximately TL 1.3 billion. Last year we had a market share of 7.74 per cent in terms of packets of medicine and 5.88 per cent in terms of turnover. From 2014 to 2015 we grew more than the market. In fact, in 2015 we grew and increased our market share more than any other company in the market. We recorded growth of around 20 per cent. How much has the market grown? In 2014 the retail pharmaceuticals market had a total volume of TL 14.6 billion. We are expecting total turnover of TL 16.8 billion at the end of 2015. What are growing the market are products with a high Turkish Lira price, more accurately biotechnology products. These include medicines for cancer and diabetes.
What are the rates of imports and exports in the pharmaceuticals sector?
Imports total $4.7 billion, while exports stand
The new regulations in the pharmaceuticals sector have resulted in a contraction in profit margins and the market has halved in value. The market leader Abdi İbrahim has experienced a similarly sized contraction in its own turnover. It suffered a major loss in 2013 in particular. The measures that the company implemented after this difficult period enabled it to expand again and record growth above the sectoral average. Abdi İbrahim Board Chair Nezih Barut has announced that their target is now to reach $ (dollars) 1 billion. They plan to realize this through company acquisitions.